Bellevue Group’s Impax Laboratories, Inc. IPXL Stock Holding History

Bellevue Group’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-75,000	Closed	-$1.46M	–	149
2018 Q1	$1.46M	Hold	75,000	–	–	0.14%	98
2017 Q4	$1.25M	Sell	75,000 -12,000	-14%	-$220K	0.13%	100
2017 Q3	$1.77M	Sell	87,000 -88,000	-50%	-$1.68M	0.18%	84
2017 Q2	$2.82M	Buy	+175,000	New	+$2.59M	0.33%	65
2016 Q4	–	Sell	-95,000	Closed	-$2.25M	–	124
2016 Q3	$2.25M	Hold	95,000	–	–	0.41%	70
2016 Q2	$2.74M	Sell	95,000 -13,000	-12%	-$424K	0.52%	60
2016 Q1	$3.46M	Buy	+108,000	New	+$3.8M	0.63%	52

Bellevue Group's IPXL Position: Q2 2018 in Review

Bellevue Group sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 75,000 shares — an estimated $1.46M sold.

Bellevue Group first reported a position in IPXL in Q1 2016 and held it in 7 quarters. The position peaked at $3.46M in Q1 2016. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.

Bellevue Group reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
Bellevue Group sold 75,000 Impax Laboratories, Inc. shares in Q2 2018, an estimated $1.46M.
Bellevue Group first reported a position in Impax Laboratories, Inc. in Q1 2016 and held it in 7 quarters.
Bellevue Group's Impax Laboratories, Inc. position peaked at $3.46M in Q1 2016.
1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.

Based on Bellevue Group's 13F filing for Q2 2018, filed 7 Aug 2018.